Variability in Long COVID Definitions and Validation of Published Prevalence Rates
JAMA Network Open · 12.08.2025 · 8 (8) · e2526506
DOI: 10.1001/jamanetworkopen.2025.26506 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JAMA Network Open, online erschienen am 12.08.2025. Verfasst von Lauren E Wisk und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Long COVID definitions vary widely, and no consensus exists on how to accurately measure its prevalence, complicating both clinical care and research.
Objective
To assess long COVID prevalence using various definitions from published literature. Design, Setting, and Participants This prospective, multicenter cohort study used data from the longitudinal Innovative Support for Patients With SARS-CoV-2 Infections Registry (INSPIRE). Participants aged 18 years or older with symptoms suggestive of COVID-19 illness at the time of their index SARS-CoV-2 test enrolled at 8 sites across the US from December 11, 2020, through August 29, 2022, with follow-up surveys collected through February 28, 2023. Exposure Positive or negative SARS-CoV-2 test result at the time of acute symptoms. Main Outcomes and Measures Long COVID prevalence among INSPIRE participants with a positive vs negative index SARS-CoV-2 test, based on long COVID definitions in published literature. Secondary outcomes were sensitivity and specificity of published definitions compared with self-reported long COVID.
Results
A total of 4575 INSPIRE participants were included (mean [SD] age, 40.40 [14.58] years). Most were female (3013 of 4448 [67.7%]) and aged 18 to 49 years (3338 of 4541 [73.5%]). Applying 5 published definitions for long COVID yielded a prevalence that ranged from 30.84% (95% CI, 29.33%-32.40%) to 42.01% (95% CI, 40.37%-43.66%) at 3 months and 14.23% (95% CI, 13.01%-15.55%) to 21.94% (95% CI, 20.47%-23.47%) at 6 months postinfection; in the 5 comparator studies, reported prevalence of long COVID at 1 to 5 months postinfection ranged from 2.6% (≥84 days) to 47.4% (3-5 months) and at 6 or more months postinfection ranged from 10.0% (95% CI, 8.8%-11.0%) to 61.9% (6-11 months). Using participants’ self-reported long COVID as a criterion standard, existing published definitions had low-to-moderate sensitivity (up to 66.32% [95% CI, 62.59%-69.90%] at 3 months and 45.53% [95% CI, 41.51%-49.60%] at 6 months) and high specificity (up to 81.29% [95% CI, 79.32%-83.15%] at 3 months and 94.26% [95% CI, 92.98%-95.37%]) at 6 months. Conclusions and Relevance In this cohort study, variability in long COVID prevalence across published definitions highlights the need for a standardized, validated definition to improve clinical recognition and research comparability, ultimately guiding more accurate diagnosis and treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine at the University of California, Los Angeles.
- Codetta Bio Inc, Morrisville, North Carolina.
- Center for Outcomes Research and Evaluation (CORE), Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
- Department of Epidemiology, Yale School of Public Health, New Haven, Connecticut.
- Division of Infectious Diseases, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois.
- Division of Infectious Diseases, Department of Medicine, Cook County Hospital, Chicago, Illinois.
Zitieren
APA
Wisk, L. E., L'Hommedieu, M., Diaz Roldan, K., Ebna Mannan, I., Spatz, E. S., Weinstein, R. A., Venkatesh, A. K., Gottlieb, M., Huebinger, R., Rising, K. L., Montoy, J. C. C., Stephens, K. A., Rodriguez, R. M., Hill, M. J., O'Laughlin, K. N., Gentile, N. L., Idris, A. H., Li, S. X., Santangelo, M., …, & INSPIRE Group (2025). Variability in Long COVID Definitions and Validation of Published Prevalence Rates. JAMA Network Open, 8(8), e2526506. https://doi.org/10.1001/jamanetworkopen.2025.26506
Vancouver
Wisk LE, L'Hommedieu M, Diaz Roldan K, Ebna Mannan I, Spatz ES, Weinstein RA, et al. Variability in Long COVID Definitions and Validation of Published Prevalence Rates. JAMA Network Open. 2025;8(8):e2526506. doi:10.1001/jamanetworkopen.2025.26506
BibTeX
@article{Wisk2025,
author = {Wisk, Lauren E and L'Hommedieu, Michelle and Diaz Roldan, Kate and Ebna Mannan, Imtiaz and Spatz, Erica S and Weinstein, Robert A and Venkatesh, Arjun K and Gottlieb, Michael and Huebinger, Ryan and Rising, Kristin L and Montoy, Juan Carlos C and Stephens, Kari A and Rodriguez, Robert M and Hill, Mandy J and O'Laughlin, Kelli N and Gentile, Nicole L and Idris, Ahamed H and Li, Shu-Xia and Santangelo, Michelle and Kean, Efrat R and McDonald, Samuel A and Gatling, Kristyn and Elmore, Joann G and INSPIRE Group, INSPIRE Group},
title = {Variability in Long COVID Definitions and Validation of Published Prevalence Rates},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {8},
pages = {e2526506},
doi = {10.1001/jamanetworkopen.2025.26506}
}
EUVIMED